DEPARTMENT.FACULTY
- DEPARTMENT_STAFF.QUALIFICATION
M.B.B.S. (AMU), M.D. Medicine (AIIMS), D.M. Cardiology (AIIMS)
- DEPARTMENT_STAFF.DESIGNATION
Professor
- DEPARTMENT_STAFF.THRUST_AREA
Interventional Cardiology
- DEPARTMENT_STAFF.ADDRESS
- DEPARTMENT_STAFF.MOBILE
8126320218
- DEPARTMENT_STAFF.EMAIL
malikazharuddin@gmail.com
After completing my MBBS from J.N. Medical College of Aligarh Muslim University, I did my Post-Graduation (M.D. in Medicine) from All India Institute of Medical Sciences, New Delhi. After my Post graduation I joined JNMC, AMU as Assistant Professor in the Department of Medicine. During my tenure as Assistant Professor I had taken study leave to pursue DM (Cardiology) from AIIMS, New Delhi and subsequently joined back the Department of Medicine as Associate Professor. I have now been transferred to Department of cardiology for better utilization of my expertise and currently serving as Professor, Department of Cardiology, JN Medical College.
- Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-? Download PDF
There is increasing recognition of association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD). Metabolic syndrome is common in both NAFLD and cardiovascular diseases. Our data indicates that NALD is highly prevalent in patients of cardiovascular disease (69.2%) and is significantly associated with metabolic syndrome and its individual components. The levels of hs-CRP and TNF-? were significantly higher in patients with NAFLD and showed an increasing trend with the severity of fatty liver.
- Angiographic outcomes in STEMI patients receiving fibrinolysis with guideline directed optimal antithrombotic therapy Download PDF
STEMI is a major public health problem requiring timely reperfusion. Fibrinolysis remains prevalent reperfusion strategy where timely primary percutaneous coronary intervention (PCI) cannot be performed. Adjunctive antithrombotic agents are of utmost importance for maximizing the benefit of fibrinolysis. This prospective study evaluates the angiographic outcomes in STEMI patients receiving fibrinolysis with optimal antithrombotic therapy and reported TIMI 3 flow rates of 33.8% and 41.5% for streptokinase and reteplase respectively, that were significantly higher than various prior studies. This data reiterates the utility of thrombolysis in resource limited settings.